We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

195 hedge funds and large institutions have $1.7B invested in Enanta Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 73 increasing their positions, 59 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 15

43% more capital invested

Capital invested by funds: $1.19B → $1.7B (+$508M)

24% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 59

7% more funds holding

Funds holding: 183 → 195 (+12)

4.86% more ownership

Funds ownership: 86.75% → 91.61% (+4.9%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

32% less call options, than puts

Call options by funds: $5.14M | Put options by funds: $7.51M

Holders
195
Holders Change
+12
Holders Change %
+6.56%
% of All Funds
4.22%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
29
Increased
73
Reduced
59
Closed
15
Calls
$5.14M
Puts
$7.51M
Net Calls
-$2.38M
Net Calls Change
-$2.5M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$26.5M
2
Ameriprise
Ameriprise
Minnesota
+$23.1M
3
Citadel Advisors
Citadel Advisors
Florida
+$21.5M
4
O
OrbiMed
New York
+$20.9M
5
MWNA
Marshall Wace North America
New York
+$18.6M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$13.6M
2
AC
Armistice Capital
New York
-$11.5M
3
Morgan Stanley
Morgan Stanley
New York
-$10.3M
4
GPP
Great Point Partners
Connecticut
-$10.2M
5
Goldman Sachs
Goldman Sachs
New York
-$6.74M
Name Holding Trade Value Shares
Change 		Change in
Stake
AAM
126
Advisors Asset Management
Colorado
$381K +$358K +3,990 New
PI
127
PineBridge Investments
New York
$374K +$6.01K +67 +2%
APA
128
American Portfolios Advisors
New York
$368K +$101K +1,122 +41%
AIM
129
Assured Investment Management
New York
$368K -$17.9K -200 -5%
CSS
130
Cubist Systematic Strategies
Connecticut
$356K +$36.5K +407 +12%
TAM
131
THB Asset Management
Connecticut
$341K +$320K +3,572 New
QT
132
Quantamental Technologies
New York
$336K +$315K +3,515 New
BNP Paribas Financial Markets
133
BNP Paribas Financial Markets
France
$334K +$313K +3,492 +58,200%
EP
134
Elkfork Partners
Oregon
$292K – – –
DTL
135
Dynamic Technology Lab
Singapore
$290K +$273K +3,039 New
ECM
136
Everence Capital Management
Indiana
$286K +$268K +2,990 New
Mackenzie Financial
137
Mackenzie Financial
Ontario, Canada
$278K -$8.07K -90 -3%
BFO
138
Boston Family Office
Massachusetts
$263K +$247K +2,750 New
AB
139
Amalgamated Bank
New York
$261K +$245K +2,736 New
OAM
140
Origin Asset Management
United Kingdom
$259K – – –
VF
141
Virtu Financial
New York
$258K +$242K +2,702 New
BAM
142
Blueshift Asset Management
New Jersey
$251K +$235K +2,623 New
GHCM
143
Glen Harbor Capital Management
California
$241K – – –
ADEF
144
Adams Diversified Equity Fund
Maryland
$220K -$233K -2,600 -53%
RCM
145
Riverhead Capital Management
Delaware
$220K – – –
XK
146
Xact Kapitalforvaltning
Sweden
$210K -$108K -1,200 -35%
Victory Capital Management
147
Victory Capital Management
Texas
$207K -$72.6K -809 -27%
MCIM
148
Meadow Creek Investment Management
Georgia
$189K – – –
SG Americas Securities
149
SG Americas Securities
New York
$187K -$445K -4,956 -72%
Walleye Trading
150
Walleye Trading
New York
$161K +$57.9K +646 +62%
4 5
6
7 8

ENTA Hedge Fund Activity: Q1 2019 in Review

195 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2019, worth a combined $1.7B — up 43% from $1.19B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ENTA positions and 15 closed out — a net gain of 14 holders — while 73 added to existing stakes and 59 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $26.5M. The largest seller was Renaissance Technologies, cutting an estimated $13.6M.

  • 195 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2019, up from 183 in Q4 2018.
  • Funds reported $1.7B of Enanta Pharmaceuticals stock for Q1 2019, up 43% quarter-over-quarter.
  • 29 funds opened new Enanta Pharmaceuticals positions in Q1 2019 and 15 closed out, a net change of +14 holders.
  • The largest Enanta Pharmaceuticals buyer in Q1 2019 was T. Rowe Price Associates, an estimated $26.5M added.
  • The largest Enanta Pharmaceuticals seller in Q1 2019 was Renaissance Technologies, an estimated $13.6M sold.

Based on aggregated 13F filings for Q1 2019.